Olema Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) will participate in three investor conferences in November 2025: a Guggenheim fireside chat on Nov 10, 2025 at 10:30 a.m. ET in Boston; a UBS presentation on Nov 12, 2025 at 8:00 a.m. ET in Palm Beach; and a Jefferies London fireside chat on Nov 19, 2025 at 9:00 a.m. GMT / 4:00 a.m. ET in London.

Live webcasts and recordings will be available, as permitted by event hosts, in the Events and Presentations section of Olema’s investor relations site at ir.olema.com.

News Market Reaction

-6.13%

1 alert

-6.13% News Effect

-$38M Valuation Impact

$578M Market Cap

0.6x Rel. Volume

On the day this news was published, OLMA declined 6.13%, reflecting a notable negative market reaction. This price movement removed approximately $38M from the company's valuation, bringing the market cap to $578M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

Guggenheim 2^nd Annual Healthcare Innovation Conference
Date and Time: November 10, 2025 at 10:30 a.m. ET
Format: Fireside Chat
Location: Boston, MA

UBS Global Healthcare Conference 2025
Date and Time: November 12, 2025 at 8:00 a.m. ET
Format: Presentation
Location: Palm Beach, FL

2025 Jefferies London Healthcare Conference
Date and Time: November 19, 2025 at 9:00 a.m. GMT / 4:00 a.m. ET
Format: Fireside Chat
Location: London

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

When will Olema Oncology (OLMA) present at the Guggenheim Healthcare Innovation Conference?

Olema will present in a fireside chat on November 10, 2025 at 10:30 a.m. ET in Boston.

What time and format is the Olema (OLMA) presentation at the UBS Global Healthcare Conference 2025?

Olema will present a presentation on November 12, 2025 at 8:00 a.m. ET in Palm Beach.

When is Olema (OLMA) scheduled to appear at the Jefferies London Healthcare Conference?

Olema will hold a fireside chat on November 19, 2025 at 9:00 a.m. GMT / 4:00 a.m. ET in London.

Will Olema (OLMA) webcasts of the conference presentations be available?

Live webcasts and recordings will be available as permitted by event hosts on Olema’s investor relations site at ir.olema.com.

Where can investors find Olema (OLMA) presentation materials and recordings after the events?

Presentation materials and any available recordings will be posted in the Events and Presentations section of ir.olema.com.